Recent Updates
Recently added Catalysts
LFCR Negative Sentiment

LIFECORE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against Lifecore Biomedical, Inc. for alleged failures in financial reporting and internal controls. The lawsuit covers claims between October 2020 and March 2024, during which the company's share price witnessed a decline. Allegations include inaccurate financial statements that require restatement and ineffective remediation efforts. Investors who acquired shares during the specified period are encouraged to contact the filing law firm for more details.
Price reaction · baseline $6.33 (2024-07-31 close) · hit after-hours · 1 other LFCR headline(s) in the window, move may be shared
day 0 close · peak
-4.7%

Market Sentiment Analysis

CONCERNS & RISKS

  • Lifecore has been subjected to a class action lawsuit for alleged deficiencies in financial reporting.
  • The company's share price has declined significantly due to disclosures of material weaknesses.
  • Accusations include inaccurate financial statements and ineffective remediation efforts.
  • Lifecore faces challenges in timely filing reports with the SEC, affecting its compliance with NASDAQ.

Full Press Release Details

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Lifecore securities between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”). Investors have until September 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
Between September 2022 and February 2024, Lifecore’s share price declined in response to a series of disclosures concerning material weaknesses in internal control over financial reporting, and delays in making required filings with the U.S. Securities and Exchange Commission (SEC).
The lawsuit alleges that (i) Lifecore maintained deficient internal controls over financial reporting; (ii) as a result, the Company issued several financial statements that were inaccurate and would need to be restated; (iii) Lifecore’s purported remediation efforts with respect to the foregoing deficiencies were ineffective; (iv) all of the foregoing impaired Lifecore’s ability to timely file periodic reports with the SEC in compliance with NASDAQ listing requirements; and (v) accordingly, the Company’s financial position and/or prospects were materially overstated.
If you purchased or otherwise acquired Lifecore shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the Lifecore Biomedical class action about?

The lawsuit alleges Lifecore had poor internal controls, leading to inaccurate financial statements.

What is the deadline to join the Lifecore lawsuit?

Investors must apply by September 27, 2024, to be appointed as lead plaintiff.

When was Lifecore's share price decline reported?

The decline occurred between September 2022 and February 2024 due to disclosure issues.

Who can participate in the Lifecore class action?

Individuals or entities that purchased Lifecore securities within the Class Period can participate.

How can I contact Bragar Eagel & Squire for more information?

You can reach them via email at investigations@bespc.com or call (212) 355-4648.

Last updated: Aug 1, 2024